279 related articles for article (PubMed ID: 15607551)
1. A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem.
Jeffrey Fessel W
Med Hypotheses; 2005; 64(2):261-3. PubMed ID: 15607551
[TBL] [Abstract][Full Text] [Related]
2. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
3. Functional domains of APOBEC3G required for antiviral activity.
Li J; Potash MJ; Volsky DJ
J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
[TBL] [Abstract][Full Text] [Related]
4. T Lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner.
Vallanti G; Lupo R; Federico M; Mavilio F; Bovolenta C
Mol Ther; 2005 Oct; 12(4):697-706. PubMed ID: 16039909
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
Goncalves J; Santa-Marta M
Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
Stopak K; de Noronha C; Yonemoto W; Greene WC
Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
[TBL] [Abstract][Full Text] [Related]
7. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
Conticello SG; Harris RS; Neuberger MS
Curr Biol; 2003 Nov; 13(22):2009-13. PubMed ID: 14614829
[TBL] [Abstract][Full Text] [Related]
8. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
Mehle A; Strack B; Ancuta P; Zhang C; McPike M; Gabuzda D
J Biol Chem; 2004 Feb; 279(9):7792-8. PubMed ID: 14672928
[TBL] [Abstract][Full Text] [Related]
9. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
Sheehy AM; Gaddis NC; Malim MH
Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
[TBL] [Abstract][Full Text] [Related]
10. New insights into the role of Vif in HIV-1 replication.
Schröfelbauer B; Yu Q; Landau NR
AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
[TBL] [Abstract][Full Text] [Related]
11. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
Marin M; Rose KM; Kozak SL; Kabat D
Nat Med; 2003 Nov; 9(11):1398-403. PubMed ID: 14528301
[TBL] [Abstract][Full Text] [Related]
13. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
[TBL] [Abstract][Full Text] [Related]
14. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.
Kao S; Miyagi E; Khan MA; Takeuchi H; Opi S; Goila-Gaur R; Strebel K
Retrovirology; 2004 Sep; 1():27. PubMed ID: 15373943
[TBL] [Abstract][Full Text] [Related]
15. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
Liu B; Yu X; Luo K; Yu Y; Yu XF
J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
Santa-Marta M; Aires da Silva F; Fonseca AM; Rato S; Goncalves J
Mol Immunol; 2007 Jan; 44(4):583-90. PubMed ID: 16580072
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
Guo F; Cen S; Niu M; Saadatmand J; Kleiman L
J Virol; 2006 Dec; 80(23):11710-22. PubMed ID: 16971427
[TBL] [Abstract][Full Text] [Related]
18. APOBEC3G targets human T-cell leukemia virus type 1.
Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
[TBL] [Abstract][Full Text] [Related]
19. The viral infectivity factor (Vif) of HIV-1 unveiled.
Rose KM; Marin M; Kozak SL; Kabat D
Trends Mol Med; 2004 Jun; 10(6):291-7. PubMed ID: 15177194
[TBL] [Abstract][Full Text] [Related]
20. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.
Pace C; Keller J; Nolan D; James I; Gaudieri S; Moore C; Mallal S
J Virol; 2006 Sep; 80(18):9259-69. PubMed ID: 16940537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
